Insulin Resistance News and Research

RSS

Insulin Resistance is a condition in which the body does not respond to insulin properly. This is most common in Type II diabetes or associated with obesity, ketoacidosis, infection, and certain rare conditions. Diminished effectiveness of insulin in lowering blood glucose levels requiring 200 units or more of insulin per day to prevent hyperglycemia or ketosis.

p62 and ERK proteins lead to development of obesity and insulin resistance, say scientists

New research by University of Cincinnati scientists implicates a new protein in obesity development and highlights a protein pair's "team effort" in regulating obesity and insulin resistance.

15 Feb 2010

White rye flour bread leads to better insulin and blood sugar levels than wheat bread with rye bran

Wholegrain bread is good and good for you, as most people know. But it is not only the fiber-rich bran, the outer shell of the grain, that is healthful. On the contrary, research at the Lund University Faculty of Engineering shows that bread baked with white rye flour, which is flour made from the inner, white part of the rye kernel, leads to better insulin and blood sugar levels compared with wheat bread with rye bran. White rye flour thus leads to much better values than both regular wheat flour and rye bran. At the same time, much of the bread that is sold in stores today in most countries is in fact baked with wheat flour and bran from various grains.

12 Feb 2010

Center for Adolescent Bariatric Surgery performs 100th LAGB procedure

Few treatments are available to help obese adolescents who are unable to lose weight and are already suffering from obesity-related health problems. Laparoscopic adjustable gastric banding (LAGB), an option for adults in the United States since 2001, is showing promise for teens. The Center for Adolescent Bariatric Surgery, which opened at NewYork-Presbyterian Morgan Stanley Children's Hospital in 2006, recently performed its 100th LAGB procedure.

12 Feb 2010

$TZD drug may increase fracture risk in older women$

TZD drug may increase fracture risk in older women

A Henry Ford Hospital study finds women with type 2 diabetes who take a commonly prescribed class of medications to treat insulin resistance may be at a higher risk for developing bone fractures.

10 Feb 2010

Researchers uncover new mechanism to protect individuals from serious complications of obesity

Although obesity is a risk factor for diabetes and coronary heart disease worldwide, only some obese individuals go on to develop these metabolic complications, while others are relatively protected. Defining these protective factors could help scientists prevent disease in the wider population.

4 Feb 2010

Study: Fat tissue in women with PCOS produces inadequate amount of hormone

Fat tissue in women with Polycystic Ovary Syndrome produces an inadequate amount of the hormone that regulates how fats and glucose are processed, promoting increased insulin resistance and inflammation, glucose intolerance, and greater risk of diabetes and heart disease, according to a study conducted at the Center for Androgen-Related Research and Discovery at Cedars-Sinai Medical Center.

3 Feb 2010

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Repros Therapeutics Inc. today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal® in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.

3 Feb 2010

Fat tissue in PCOS patients may predispose them to diabetes and heart disease

3 Feb 2010

Women's metabolic disorder remains largely undiagnosed

Gail Donnelly's classmates nicknamed her "Knobby" because she was so skinny all her bones seemed to poke out from under her skin. But when Donnelly turned 27, that once knobby frame disappeared under mysteriously ballooning weight.

2 Feb 2010

Research could help in developing more specific treatments for Type 2 diabetes

New research on Type 2 diabetes by Trinity College Dublin researchers could benefit young adults (aged 18-25 years) with the condition. The research led by Professor John Nolan of Trinity College Dublin and St James's Hospital, Dublin, has just been published online in the leading international journal, Diabetes Care.

2 Feb 2010

Obesity and type 2 diabetes in younger people can increase risk of stroke and heart attack

People who are obese and have type 2 diabetes in their 20s will be at higher risk of having a heart attack or stroke in their 40s if they do not change their lifestyle.

30 Jan 2010

Health benefits of aerobics can be greatly affected by what you eat after exercise

Many of the health benefits of aerobic exercise are due to the most recent exercise session (rather than weeks, months and even years of exercise training), and the nature of these benefits can be greatly affected by the food we eat afterwards, according to a study published in the Journal of Applied Physiology (http://jap.physiology.org).

29 Jan 2010

Alli boosts weight loss and reduces excess visceral fat

New studies show that overweight and obese people using alli® (orlistat 60 mg) with a reduced calorie, lower-fat diet can significantly reduce weight, visceral fat, and waist circumference and therefore may reduce their risk of type 2 diabetes, hypertension, heart disease and stroke.

28 Jan 2010

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.

28 Jan 2010

Findings may point toward potential therapies for type 2 diabetes

In people who put on a lot of weight, or whose bodies start developing the inability to use insulin effectively that leads toward type 2 diabetes, the pancreas typically ramps up its supply of insulin-generating "beta" cells, at least partly by replication of the existing cells.

27 Jan 2010

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Novo Nordisk, a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

27 Jan 2010

The American Journal of Pathology: Highlights from February 2010 issue

A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer. Their report can be found in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

Five questions for successful weight loss

The American Society of Bariatric Physicians (ASBP) works with physicians so they’re better prepared to deal with society’s obesity epidemic. Even though people focus on weight loss more in January than any other month, successful weight loss is a year-round long-term initiative that goes far beyond just diet and exercise. The ASBP has highlighted five questions everyone who needs to lose weight should ask their physician.

21 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

MAGIC investigators identify new genetic variants that influence insulin and glucose regulation

An international research consortium has found 13 new genetic variants that influence blood glucose regulation, insulin resistance, and the function of insulin-secreting beta cells in populations of European descent. Five of the newly discovered variants increase the risk of developing type 2 diabetes, the most common form of diabetes.

18 Jan 2010

Insulin Resistance News and Research

Further Reading

p62 and ERK proteins lead to development of obesity and insulin resistance, say scientists

White rye flour bread leads to better insulin and blood sugar levels than wheat bread with rye bran

Center for Adolescent Bariatric Surgery performs 100th LAGB procedure

TZD drug may increase fracture risk in older women

Researchers uncover new mechanism to protect individuals from serious complications of obesity

Study: Fat tissue in women with PCOS produces inadequate amount of hormone

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Fat tissue in PCOS patients may predispose them to diabetes and heart disease

Women's metabolic disorder remains largely undiagnosed

Research could help in developing more specific treatments for Type 2 diabetes

Obesity and type 2 diabetes in younger people can increase risk of stroke and heart attack

Health benefits of aerobics can be greatly affected by what you eat after exercise

Alli boosts weight loss and reduces excess visceral fat

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

Findings may point toward potential therapies for type 2 diabetes

FDA approves Novo Nordisk's Victoza for type 2 diabetes

The American Journal of Pathology: Highlights from February 2010 issue

Five questions for successful weight loss

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

MAGIC investigators identify new genetic variants that influence insulin and glucose regulation

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News